Nasser Abdalla Dhayat

Dr. Nasser Abdalla Dhayat

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 October 2007 in Basic Research in Cardiology
Verified
Journal Article
Closed access
PDF file
DWD. Westermann
D. Westermann
SLS. Linthout
S. Linthout
SDS. Dhayat
S. Dhayat
Nasser Abdalla DhayatNasser Abdalla Dhayat
Nasser Abdalla Dhayat
ASA. Schmidt
A. Schmidt
CTC. Tschöpe
C. Tschöpe

17 March 2008 in Basic Research in Cardiology
Verified
Journal Article
Closed access
PDF file
SLSophie Linthout
Sophie Linthout
USUte Seeland
Ute Seeland
ARAlexander Riad
Alexander Riad
OEOleg Eckhardt
Oleg Eckhardt
MHMathias Hohl
Mathias Hohl
CTCarsten Tschöpe
Carsten Tschöpe

2 March 2023 in New England Journal of Medicine
Verified
Journal Article
Closed access
Nasser Abdalla DhayatNasser Abdalla Dhayat
Nasser Abdalla Dhayat
OBOlivier Bonny
Olivier Bonny
BRBeat Roth
Beat Roth
ACAndreas Christe
Andreas Christe
ARAlexander Ritter
Alexander Ritter
DFDaniel G. Fuster
Daniel G. Fuster
Nephrolithiasis is one of the most common conditions affecting the kidney and is characterized by a high risk of recurrence. Thiazide diuretic agents are widely used for prevention of the recurrence of kidney stones, but data regarding the efficacy of such agents as compared with placebo are limited. Furthermore, dose-response data are also limited. In this double-blind trial, we randomly assigned patients with recurrent calcium-containing kidney stones to receive hydrochlorothiazide at a dose of 12.5 mg, 25 mg, or 50 mg once daily or placebo once daily. The main objective was to investigate the dose-response effect for the primary end point, a composite of symptomatic or radiologic recurrence of kidney stones. Radiologic recurrence was defined as the appearance of new stones on imaging or the enlargement of preexisting stones that had been observed on the baseline image. Safety was also assessed. In all, 416 patients underwent randomization and were followed for a median of 2.9 years. A primary end-point event occurred in 60 of 102 patients (59%) in the placebo group, in 62 of 105 patients (59%) in the 12.5-mg hydrochlorothiazide group (rate ratio vs. placebo, 1.33; 95% confidence interval [CI], 0.92 to 1.93), in 61 of 108 patients (56%) in the 25-mg group (rate ratio, 1.24; 95% CI, 0.86 to 1.79), and in 49 of 101 patients (49%) in the 50-mg group (rate ratio, 0.92; 95% CI, 0.63 to 1.36). There was no relation between the hydrochlorothiazide dose and the occurrence of a primary end-point event (P = 0.66). Hypokalemia, gout, new-onset diabetes mellitus, skin allergy, and a plasma creatinine level exceeding 150% of the baseline level were more common among patients who received hydrochlorothiazide than among those who received placebo. Among patients with recurrent kidney stones, the incidence of recurrence did not appear to differ substantially among patients receiving hydrochlorothiazide once daily at a dose of 12.5 mg, 25 mg, or 50 mg or placebo once daily. (Funded by the Swiss National Science Foundation and Inselspital; NOSTONE ClinicalTrials.gov number, NCT03057431.).

1 July 2007 in Diabetes
Verified
Journal Article
Closed access
PDF file
DWDirk Westermann
Dirk Westermann
SLSophie Van Linthout
Sophie Van Linthout
SDSameer Dhayat
Sameer Dhayat
Nasser Abdalla DhayatNasser Abdalla Dhayat
Nasser Abdalla Dhayat
FEFelicitas Escher
Felicitas Escher
CTCarsten TschöpE
Carsten TschöpE
OBJECTIVE—We investigated the effect of pharmacological inhibition of the interleukin converting enzyme (ICE) on cardiac inflammation, apoptosis, fibrosis, and left ventricular function in an animal model of diabetes. RESEARCH DESIGN AND METHODS—Diabetes was induced in 24 Sprague-Dawley rats by injection of streptozotozin (STZ) (70 mg/kg). Diabetic animals were treated with the interleukin converting enzyme (ICE) inhibitor (ICEI) (n = 12) or with a placebo (n = 12). Nondiabetic rats served as controls (n = 12). Left ventricular function was documented 6 weeks after induction of diabetes. Cardiac tissue was analyzed for the expression of cytokines, intracellular adhesion molecule-1 and vascular cell adhesion molecule-1, leukocyte and macrophage integrins, and collagen. Phosphorylation of Akt was analyzed by Western blot and apoptosis by Blc-2 and Bax measurements. RESULTS—Left ventricular function was significantly impaired in diabetic animals. This was accompanied by a significant increase of cytokines, cell adhesion molecules, leukocytes and macrophages, and collagen content. In addition, the phosphorylation state of Akt was reduced. These changes were significantly attenuated in the diabetic group treated with ICEI. CONCLUSIONS—Cardiac dysfunction is associated with cardiac inflammation in experimental diabetic cardiomyopathy. Both of these—cardiac dysfunction and inflammation—are attenuated after treatment with ICEI. These data suggest that anticytokine-based therapies might be beneficial in diabetic cardiomyopathy.

23 June 2007 in Diabetologia
Verified
Journal Article
Closed access
PDF file
SLS. Van Linthout
S. Van Linthout
ARA. Riad
A. Riad
Nasser Abdalla DhayatNasser Abdalla Dhayat
Nasser Abdalla Dhayat
FSF. Spillmann
F. Spillmann
JDJ. Du
J. Du
CTC. Tschöpe
C. Tschöpe

1 September 2016 in Kidney International
Verified
Journal Article
Closed access
Nasser Abdalla DhayatNasser Abdalla Dhayat
Nasser Abdalla Dhayat
DADaniel Ackermann
Daniel Ackermann
Menno PruijmMenno Pruijm
Menno Pruijm
BPBelen Ponte
Belen Ponte
GEGeorg Ehret
Georg Ehret
DFDaniel G. Fuster
Daniel G. Fuster